Onychomycosis

  • Danya Reich
  • Corinna Eleni Psomadakis
  • Bobby Buka
Chapter

Abstract

Onychomycosis is a common fungal infection of the nails, typically caused by the dermatophyte Trichophyton rubrum. The condition is often preceded by a fungal infection of the skin of the foot called tinea pedis. Onychomycosis causes the affected nail to thicken and typically develop a yellow discoloration. Oral antifungals are the most effective treatment for onychomycosis, which should be commenced after confirming the diagnosis via PAS staining and ensuring the patient has good liver function. Topical treatment is available in the form of ciclopirox or efinaconazole lacquers, which are safer yet less effective than oral antifungals.

Keywords

Onychomycosis Dermatophytosis Dermatophyte Fungus Fungal infection Toenail Trichophyton rubrum Candida albicans Tinea pedis Yellow nail PAS stain Onycholysis Nail culture Jublia Ciclopirox Penlac Terbinafine Antifungal 

References

  1. 1.
    Lipner SR, Scher RK. Onychomycosis: current and investigational therapies. Cutis. 2014;94(6):E21–4.PubMedGoogle Scholar
  2. 2.
    Hay RJ, Baran R. Why should we care if onychomycosis is truly onychomycosis? Br J Dermatol. 2015;172(2):316–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Schieke SM, Garg A. Chapter 188. Superficial fungal infection. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, editors. Fitzpatrick’s dermatology in general medicine. 8th ed. New York: McGraw-Hill; 2012. p. 2277–97.Google Scholar
  4. 4.
    Rose AE. Therapeutic update: onychomycosis. J Drugs Dermatol. 2014;13(10):1173–5.PubMedGoogle Scholar
  5. 5.
    Ghannoum MA, Hajjeh RA, Scher R, Konnikov N, Gupta AK, Summerbell R, Sullivan S, Daniel R, Krusinski P, Fleckman P, Rich P, Odom R, Aly R, Pariser D, Zaiac M, Rebell G, Lesher J, Gerlach B, Ponce-De-Leon GF, Ghannoum A, Warner J, Isham N, Elewski B. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol. 2000;43(4):641–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Daniel III CR, Gupta AK, Daniel MP, Sullivan S. Candida infection of the nail: role of Candida as a primary or secondary pathogen. Int J Dermatol. 1998;37(12):904–7.CrossRefPubMedGoogle Scholar
  7. 7.
    El-Tatawy RA, Abd El-Naby NM, El-Hawary EE, Talaat RA. A comparative clinical and mycological study of Nd-YAG laser versus topical terbinafine in the treatment of onychomycosis. J Dermatolog Treat. 2015;11:1–4.Google Scholar
  8. 8.
    Jung MY, Shim JH, Lee JH, Lee JH, Yang JM, Lee DY, Jang KT, Lee NY, Lee JH, Park JH, Park KK. Comparison of diagnostic methods for onychomycosis, and proposal of a diagnostic algorithm. Clin Exp Dermatol. 2015;40(5):479–84.CrossRefPubMedGoogle Scholar
  9. 9.
    Weinberg JM, Koestenblatt EK, Tutrone WD, Tishler HR, Najarian L. Comparison of diagnostic methods in the evaluation of onychomycosis. J Am Acad Dermatol. 2003;49(2):193–7.CrossRefPubMedGoogle Scholar
  10. 10.
    de Berker D. Clinical practice: fungal nail disease. N Engl J Med. 2009;360(20):2108–16.CrossRefPubMedGoogle Scholar
  11. 11.
    Gupta AK, Simpson FC. Efinaconazole (Jublia) for the treatment of onychomycosis. Expert Rev Anti Infect Ther. 2014;12(7):743–52.CrossRefPubMedGoogle Scholar
  12. 12.
    Gupta AK, Paquet M. Management of onychomycosis in Canada in 2014. J Cutan Med Surg. 2015;19(3):260–73.CrossRefPubMedGoogle Scholar
  13. 13.
    Evans EG, Sigurgeirsson B. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ. 1999;318(7190):1031–5.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Derby R, Rohal P, Jackson C, Beutler A, Olsen C. Novel treatment of onychomycosis using over-the-counter mentholated ointment: a clinical case series. J Am Board Fam Med. 2011;24(1):69–74.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Open Access This chapter is distributed under the terms of the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Authors and Affiliations

  • Danya Reich
    • 1
  • Corinna Eleni Psomadakis
    • 2
  • Bobby Buka
    • 3
  1. 1.Department of Family MedicineMount Sinai School of Medicine Attending Mount Sinai Doctors/Beth Israel Medical Group-WilliamsburgBrooklynUSA
  2. 2.School of Medicine Imperial College LondonLondonUK
  3. 3.Department of DermatologyMount Sinai School of MedicineNew YorkUSA

Personalised recommendations